BIND Therapeutics (BIND) Surges on Upgrade

BIND Therapeutics, Inc. (BIND) shares are trading higher by nearly 13% to $6.40 in early trading after the company was initiated this morning with an ‘Outperform’ rating and $14.00 price target by analysts at Oppenheimer. The firm’s 12-month base case estimate suggests a potential upside of 120% from the stock’s current pps.

Fundamentally, BIND shows the following financial data:

  • $40.93 million in cash in most recent quarter
  • $54.07 million t-12 total assets
  • $37.16 million total equity
  • $10.43 million t-12 revenue
  • ($32.54) million annual net income

On valuation measures, BIND Therapeutics Inc. shares have a T-12 price/sales ratio of 11.09 and a price/book for the same period of 2.52. EPS is ($1.97). The name has a market cap of $130.51 million and a median Wall Street price target of $13.00 with a high target of $25.00. Currently there are 3 analysts that rate BIND a ‘Buy’, 1 rates it a ‘Hold’. No analyst rates it a ‘Sell’.

In terms of share statistics, BIND Therapeutics Inc. has a total of 20.29 million shares outstanding with 41.63% held by insiders and 28.10% held by institutions. The stock’s short interest currently stands at 5.44%, bringing the total number of shares sold short to 557,494.

Shares of the Cambridge Massachusetts-based company are down 52.23% year-over-year ; up 5.00% year-to-date.

Be the first to comment

Leave a Reply

Your email address will not be published.


*